Abingworth LLP
Q1 2014 13F-HR Holdings
Net value change ($000)
+48,550
(36.6%)
New positions
2
Sold out positions
0
Turnover %
20.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Dicerna Pharmaceuticals Inc | 33,314 | NEW |
| AVIDITY BIOSCIENCES INC | 5,903 | 20.4% |
| SUPN | 5,040 | 18.6% |
| Regulus Therapeutics Inc. | 2,943 | NEW |
| ONCOGENEX PHARMACEUTICALS IN | 2,053 | 40.8% |
| GW PHARMACEUTICALS PLC | 1,819 | 42.8% |
| HYPERION THERAPEUTICS INC | 353 | 28.0% |
| PORTOLA PHARMACEUTICALS INC | 187 | 0.6% |
| Anthera | 127 | 9.5% |
| Zalicus Inc | 9 | 10.3% |
Top Reduces (Value $000, Stocks/ETFs)
| ZOGENIX, INC. | -1,378 | -17.2% |
| AMARIN CORP PLC | -1,213 | -7.7% |
| CEMPRA INC | -607 | -6.9% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|